Bladder Cancer

Gulley says there are currently a variety of phase III studies looking at new treatments for use in bladder cancer, despite some widely-used agents, such as nivolumab and pembrolizumab, already being approved for other cancer types like melanoma and lung cancer, though not bladder cancer.

While results from ongoing trials with atezolizumab, pembrolizumab, nivolumab, and avelumab in bladder cancer are eagerly awaited, there is one subset of patients who require special attention - patients with upper tract urothelial cancer (UTUC).

A data metaanalysis supports the potential correlation between NAT2 slow acetylation and the risk of bladder cancer.

A high number of clinically relevant genomic alterations (CRGAs) were found in patients with advanced urothelial carcinoma (UC) using a comprehensive genomic profile (CGP).

Daniel P. Petrylak, MD, talks about taking the clinical trials examining MPDL3280A a step further for bladder cancer patients.

An FDA panel voted against approval of the immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer (NMIBC) following first-line bacillus Calmette-Guerin (BCG) therapy.

Select medical centers nationwide are now offering blue-light cystoscopy imaging to better detect papillary cancer of the bladder.

Bladder cancer may soon catch up to other areas of oncology in terms of an influx of immunotherapies, according to Thomas Powles, MD.

Luciano Rossetti, MD, head of Global Scientific Strategy, Merck Research Laboratories, talks about the discovery of PD-L1 and how the finding has evolved into potential treatments for bladder cancer patients, specifically avelumab.

Mayer Fishman, MD, PhD, Medical Oncologist, Moffitt Cancer Center, talks about the phase Ib/II study of an IL-2/T-cell receptor fusion protein in combination with gemcitabine and cisplatin in advanced or metastatic chemo-refractory urothelial cancer (UC).

Researchers are investigating apaziquone for use as an intravesical treatment for patients with nonmuscle-invasive bladder cancer.

A new paper spotlights a potential biomarker and therapeutic target for bladder cancer. The authors say that although BC is recognized as a common and deadly malignancy, a lack of understanding of the molecular pathways involved has hindered development of effective treatments compared with progress made with other malignancies.

Andrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses promising treatment methods for patients with refractory, metastatic urothelial carcinoma.

Telesta Therapeutics has been granted an FDA advisory hearing to discuss the biologics license application of its MCNA immunotherapy as treatment for high-risk nonmuscle invasive bladder cancer following first-line bacillus Calmette-Guerin (BCG).

A priority review designation was recently assigned by the FDA to the intravesical immunotherapy MCNA as a treatment for patients who have high-risk non-muscle invasive bladder cancer, following first-line bacillus Calmette-Guérin (BCG) therapy.

Bishoy M. Faltas, MD, Fellow, Hematology/Oncology, Weill Cornell Medical College, discusses immunotherapy in platinum-resistant bladder cancer.

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and of Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses bacillus calmette-guerin (BCG) therapy for the treatment of patients with non-invasive bladder cancer.

While the stage of bladder cancer is influential in determining treatment strategy, a number of other factors may also affect a patient’s treatment regimen.

There is a significant need for biomarkers throughout the course of bladder cancer diagnosis and different treatment regimens.

There are several agents currently in clinical trials for the treatment of bladder cancer.

Bladder cancer affects thousands of people in the United States.

Gary D. Steinberg, MD, Bruce and Beth White Family Professor, professor of surgery, director, urologic oncology, University of Chicago Medicine, discusses the challenges in treating bladder cancer.

Bladder cancer is the fourth most prevalent cancer in the United States and is estimated to account for 7% of all new cancer cases in 2014.

Based upon the stage of disease, which is indicative of invasiveness, different treatment regimens have been adopted and are included in guidelines developed by the NCCN.

References for Evolving Paradigms in Bladder Cancer

The biomarker E2F4 predicts survival in breast cancer, and an article recently published in the journal Molecular Cancer Research indicates that E2F4 may also predict progression and immunotherapy efficacy in bladder cancer.

Patients with bladder cancer who undergo robot-assisted radical cystectomy (RARC) appear to have acceptable 5-year survival, according to the largest multi-institutional series to date to collect data on RARC outcomes in this population.

Predictive data from two major financial research and consulting firms, UBS and GlobalData, have supported atezolizumab [MPDL3280A] as a major player in the immunotherapy race for bladder cancer.

Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses bladder cancer outcomes in men vs. women.

Alexander Kutikov, MD, FACS, attending surgeon, Urologic Oncology, associate professor, Urologic Oncology, Fox Chase Cancer Center, discusses neoadjuvant chemotherapy for the treatment of patients with bladder cancer.